Geode Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-508,551
| Closed | -$5.7M | – | 4103 |
|
|
2017
Q3 | $5.7M | Buy |
508,551
+76,567
| +18% | +$845K | ﹤0.01% | 2123 |
|
|
2017
Q2 | $4.75M | Buy |
431,984
+18,702
| +5% | +$187K | ﹤0.01% | 2177 |
|
|
2017
Q1 | $4.05M | Buy |
413,282
+16,554
| +4% | +$165K | ﹤0.01% | 2236 |
|
|
2016
Q4 | $4.28M | Buy |
396,728
+21,874
| +6% | +$219K | ﹤0.01% | 2161 |
|
|
2016
Q3 | $3.84M | Buy |
374,854
+28,756
| +8% | +$313K | ﹤0.01% | 2128 |
|
|
2016
Q2 | $4.52M | Buy |
346,098
+6,232
| +2% | +$81.7K | ﹤0.01% | 1978 |
|
|
2016
Q1 | $3.74K | Buy |
339,866
+10,621
| +3% | +$94.4K | ﹤0.01% | 2056 |
|
|
2015
Q4 | $3.03M | Buy |
329,245
+1,758
| +0.5% | +$14.7K | ﹤0.01% | 2204 |
|
|
2015
Q3 | $2.27M | Sell |
327,487
-31,472
| -9% | -$270K | ﹤0.01% | 2363 |
|
|
2015
Q2 | $3.52M | Sell |
358,959
-13,427
| -4% | -$122K | ﹤0.01% | 2139 |
|
|
2015
Q1 | $3.3M | Buy |
372,386
+24,104
| +7% | +$192K | ﹤0.01% | 2114 |
|
|
2014
Q4 | $3.05M | Sell |
348,282
-85,212
| -20% | -$690K | ﹤0.01% | 2137 |
|
|
2014
Q3 | $2.99M | Buy |
433,494
+174,518
| +67% | +$1.05M | ﹤0.01% | 2117 |
|
|
2014
Q2 | $1.36M | Buy |
258,976
+3,942
| +2% | +$19.2K | ﹤0.01% | 2610 |
|
|
2014
Q1 | $1.16M | Buy |
255,034
+7,267
| +3% | +$35.1K | ﹤0.01% | 2688 |
|
|
2013
Q4 | $1.25M | Sell |
247,767
-14,751
| -6% | -$71K | ﹤0.01% | 2574 |
|
|
2013
Q3 | $1.33M | Buy |
262,518
+29,270
| +13% | +$163K | ﹤0.01% | 2430 |
|
|
2013
Q2 | $1.16M | Buy |
+233,248
| New | +$1.11M | ﹤0.01% | 2386 |
|
Geode Capital Management's SCLN Position: Q4 2017 in Review
Geode Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 508,551 shares — an estimated $5.7M sold.
Geode Capital Management first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $5.7M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Geode Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Geode Capital Management sold 508,551 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $5.7M.
- Geode Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Geode Capital Management's Sciclone Pharmaceuticals Inc position peaked at $5.7M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Geode Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.